STOCK TITAN

Stoke Therapeutics (STOK) director gifts 303,190 options to trust

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. director Seth Loring Harrison reported 16 bona fide gift transfers on July 16, 2026, moving stock options over 303,190 underlying common shares from his direct holdings to the East Pillar 2026 Irrevocable Trust. The options are fully vested, with exercise prices between $10.90 and $40.37 and expirations from 2029 to 2036. The gifts were made for no consideration and are exempt from short-swing profit liability under Rule 16b-5.

Positive

  • None.

Negative

  • None.
Insider Harrison Seth Loring
Role Director
Type Security Shares Price Value
Gift Stock Option (Right to Buy) 29,555 $0.00 --
Gift Stock Option (Right to Buy) 29,555 $0.00 --
Gift Stock Option (Right to Buy) 14,777 $0.00 --
Gift Stock Option (Right to Buy) 14,777 $0.00 --
Gift Stock Option (Right to Buy) 11,650 $0.00 --
Gift Stock Option (Right to Buy) 11,650 $0.00 --
Gift Stock Option (Right to Buy) 21,000 $0.00 --
Gift Stock Option (Right to Buy) 21,000 $0.00 --
Gift Stock Option (Right to Buy) 19,441 $0.00 --
Gift Stock Option (Right to Buy) 19,441 $0.00 --
Gift Stock Option (Right to Buy) 7,639 $0.00 --
Gift Stock Option (Right to Buy) 7,639 $0.00 --
Gift Stock Option (Right to Buy) 29,747 $0.00 --
Gift Stock Option (Right to Buy) 29,747 $0.00 --
Gift Stock Option (Right to Buy) 17,786 $0.00 --
Gift Stock Option (Right to Buy) 17,786 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Stock Option (Right to Buy) — 29,555 shares (Indirect, By Trust)
Footnotes (1)
  1. The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on March 21, 2022. The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2021. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 8, 2022. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 7, 2023. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 13, 2024. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2025. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2026. The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the Issuer on the vesting date.
Gifted option shares 303,190 shares Aggregate underlying common shares in 16 bona fide gift transactions on 2026-07-16
Gift transactions 16 transactions Number of derivative gifts (code G) of stock options reported
Lowest exercise price $10.90 per share Stock option grant expiring on 2035-06-02
Highest exercise price $40.37 per share Stock option grant expiring on 2031-06-07
Latest option expiration 2036-06-02 Expiration of option with $29.46 exercise price
bona fide gift regulatory
"Transaction code G is described as a bona fide gift of securities"
A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.
Rule 16b-5 regulatory
"Exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act"
short-swing profit liability regulatory
"Gift is exempt from short-swing profit liability pursuant to Rule 16b-5"
East Pillar 2026 Irrevocable Trust financial
"The securities are directly held by the East Pillar 2026 Irrevocable Trust"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Stoke Therapeutics (STOK) report for Seth Loring Harrison?

Stoke Therapeutics reported that director Seth Loring Harrison made 16 bona fide gifts of stock options on July 16, 2026, transferring options over 303,190 underlying common shares from his direct ownership to a trust, with no consideration received.

How many Stoke Therapeutics (STOK) option shares were transferred in this Form 4?

The filing shows gifts of stock options covering 303,190 underlying shares of Stoke Therapeutics common stock. These come from 16 derivative transactions, each involving fully vested and exercisable stock option grants with specified strike prices and expiration dates.

Who now holds the gifted Stoke Therapeutics (STOK) options reported in this filing?

The options are held indirectly by the East Pillar 2026 Irrevocable Trust. The filing states the securities are directly held by the trust, and Harrison, as a member of the trustee’s board of managers, may share voting and investment discretion and is a beneficiary.

What are the exercise prices and expirations of the gifted STOK stock options?

The gifted stock options have exercise prices ranging from $10.90 to $40.37 per share, with expiration dates between 2029-09-09 and 2036-06-02. Footnotes state each option grant involved is fully vested and exercisable as of specified prior vesting dates.

Are the Stoke Therapeutics (STOK) gift transactions exempt from short-swing rules or tied to a 10b5-1 plan?

The filing notes the gifts are exempt from short-swing profit liability under Rule 16b-5. The Rule 10b5-1 checkbox is not affirmed (set to false), indicating these transactions were not represented as being made under a Rule 10b5-1 trading plan.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Harrison Seth Loring

(Last)(First)(Middle)
C/O STOKE THERAPEUTICS, INC.
45 WIGGINS AVENUE

(Street)
BEDFORD MASSACHUSETTS 01730

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$28.807/16/2026G(1)29,555 (2)09/09/2029Common Stock29,555$00D
Stock Option (Right to Buy)$28.807/16/2026G(1)29,555 (2)09/09/2029Common Stock29,555$029,555IBy Trust(3)
Stock Option (Right to Buy)$26.5307/16/2026G(1)14,777 (4)06/02/2030Common Stock14,777$00D
Stock Option (Right to Buy)$26.5307/16/2026G(1)14,777 (4)06/02/2030Common Stock14,777$014,777IBy Trust(3)
Stock Option (Right to Buy)$40.3707/16/2026G(1)11,650 (5)06/07/2031Common Stock11,650$00D
Stock Option (Right to Buy)$40.3707/16/2026G(1)11,650 (5)06/07/2031Common Stock11,650$011,650IBy Trust(3)
Stock Option (Right to Buy)$12.9607/16/2026G(1)21,000 (6)06/06/2032Common Stock21,000$00D
Stock Option (Right to Buy)$12.9607/16/2026G(1)21,000 (6)06/06/2032Common Stock21,000$021,000IBy Trust(3)
Stock Option (Right to Buy)$12.4607/16/2026G(1)19,441 (7)06/12/2033Common Stock19,441$00D
Stock Option (Right to Buy)$12.4607/16/2026G(1)19,441 (7)06/12/2033Common Stock19,441$019,441IBy Trust(3)
Stock Option (Right to Buy)$16.4107/16/2026G(1)7,639 (8)06/04/2034Common Stock7,639$00D
Stock Option (Right to Buy)$16.4107/16/2026G(1)7,639 (8)06/04/2034Common Stock7,639$07,639IBy Trust(3)
Stock Option (Right to Buy)$10.907/16/2026G(1)29,747 (9)06/02/2035Common Stock29,747$00D
Stock Option (Right to Buy)$10.907/16/2026G(1)29,747 (9)06/02/2035Common Stock29,747$029,747IBy Trust(3)
Stock Option (Right to Buy)$29.4607/16/2026G(1)17,786 (10)06/02/2036Common Stock17,786$00D
Stock Option (Right to Buy)$29.4607/16/2026G(1)17,786 (10)06/02/2036Common Stock17,786$017,786IBy Trust(3)
Explanation of Responses:
1. The reported transaction represents a gift, for no consideration, of shares of the Issuer's Common Stock, which is exempt from short-swing profit liability pursuant to Rule 16b-5 under the Exchange Act of 1934, as amended.
2. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on March 21, 2022.
3. The securities are directly held by the East Pillar 2026 Irrevocable Trust (the "Trust"). The reporting person is a member of the board of managers of the Trust's trustee and may be deemed to exercise voting discretion, as well as shared investment discretion, in such capacity. The reporting person and certain of his immediate family members are beneficiaries of the Trust.
4. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2021.
5. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 8, 2022.
6. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 7, 2023.
7. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 13, 2024.
8. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2025.
9. This option is fully vested and exercisable. Pursuant to the grant agreement between the Issuer and the reporting person, the award became fully vested on June 3, 2026.
10. The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the Issuer on the vesting date.
/s/ Jonathan Allan, Attorney-in-Fact07/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)